ALİ SERDAR OĞUZOĞLU, NİLGÜN ŞENOL, DUYGU DOGUC, ŞERİFE TAŞAN, YALÇIN ERZURUMLU, HALİL AŞCI
Süleyman Demirel Üniversitesi Tıp Fakültesi Dergisi - 2025;32(1):27-35
Objective: This research seeks to determine whether nebivolol (NEB) can prevent brain damage caused by lipopolysaccharide (LPS). Material and method: The thirty-two female Wistar Albino rats were divided into four groups, each containing eight rats: LPS (5mg/kg single dose i.p.), Control, LPS+NEB, and NEB (1 ml of 10 kg mg/kg given by oral gavage every day for three days). In brain tissues, the following parameters were measured: tumor necrosis factor-alpha (TNF-α), vascular endothelial growth factor A (VEGFA), caspase-3 (Cas-3), total antioxidant status (TAS), total oxidant status (TOS), and oxidative stress index (OSI). Results: In the LPS group, there was an increase in the levels of TOS, VEGFA, Cas-3, and TNF-α. NEB therapy markedly reduced TOS, VEGFA, TNF-α, and Cas-3 levels. In both the control and NEB groups, histopathological analysis of the brain, hippocampus, and cerebellum demonstrated normal tissue architecture. In the LPS group, there were mild to moderate hemorrhages and severe hyperemia in the meningeal and parenchymal arteries of the brain and cerebellum. The LPS + NEB group’s histopathology results were significantly ameliorated by NEB treatment. Conclusion: NEB treatments anti-inflammatory, anti-apoptotic, and antioxidant characteristics helped mitigate the brain damage caused by LPS. NEB may help to reduce the severity of LPS-induced damage.
